After the founder of Sunflower Pharmaceutical killed his wife, his daughter joined hands to take over the plate for 3 years! Who remembers "Little Sunflower Mom Classroom"?

Founder Guan Yanbin"'s "wife killing case" In the past three years, Sunflower Pharmaceutical (002737. SZ) is gradually coming out of the haze.

On the evening of April 21, Sunflower Pharmaceutical disclosed its 2021 performance report, and its net profit increased twice. The report shows that in 2021, the company's operating income was 4.461 billion yuan, an increase of 28.86% over 2020, and the net profit attributable to the mother was 705 million yuan, an increase of 20.58% over 2020. The next day, Sunflower Pharmaceutical's stock price quickly rose to a limit after opening low, closing at 15.52 yuan / share, with a total market value of 9.064 billion yuan.

Sunflower Pharmaceutical is a large-scale brand pharmaceutical group enterprise that is dominated by the production of proprietary Chinese medicines, with chemical drugs, biological drugs and health care products as the two wings, integrating drug research and development, manufacturing and marketing. Sunflower pharmaceutical products are numerous, especially the children's medicine "Little Sunflower" brand is the most well-known.

In 2021, what really helps Sunflower Pharmaceutical to counterattack is chemical drugs. In the whole year, its proprietary Chinese medicines achieved revenue of 3.203 billion yuan, an increase of 20.77% year-on-year; chemical drug revenue of 1.144 billion yuan, an increase of 63.68% year-on-year, a record high.

On April 22, the Times Weekly reporter contacted the secretary of the board of directors of Sunflower Pharmaceutical as an investor. The staff said that the growth of net profit within 30% of revenue is a normal performance change, and does not need to be explained separately, "The company is considering gradually expanding the proportion of chemical drug revenue, but in the short term, it is still based on proprietary Chinese medicines." ”

The father killed his wife and went to prison, and the sisters joined forces to take office

Sunflower Pharmaceutical was established in 2005 and was restructured from the state-owned Wuchang Pharmaceutical Factory in Heilongjiang Province.

In 2014, Sunflower Pharmaceutical landed on the Shenzhen Stock Exchange, with a total market value of 20 billion yuan. With the help of the capital market, the development of Sunflower Pharmaceutical has accelerated. Four years later, it achieved sales of 63 varieties exceeding 10 million, and 11 varieties of sales exceeded 100 million, becoming the "king of OTC".

Guan Yanbin was full of ambition, and shouted to the outside world in 2018, "Give me another 20 years, and return you a hundred billion sunflowers!" ”

Things are unpredictable. The "wife killing case" at the end of that year became a watershed in the development of Sunflower Pharmaceutical. On December 22, 2018, Guan Yanbin and his ex-wife Zhang Xiaolan caused a bloody case due to verbal altercation.

According to media reports, Zhang Xiaolan was dissatisfied with Guan Yanbin's personal autobiography "Hanging Kettle Wind Song", believing that the book did not truthfully tell her contribution to sunflower pharmaceutical industry, and said that she also wanted to write a book about the history of sunflower pharmaceutical development, but also to disclose Guan Yanbin's extramarital affair.

In anger, Guan Yanbin slashed Zhang Xiaolan 4 times with a kitchen knife. After rescue, although Zhang Xiaolan retrieved a life, he was seriously injured and became a vegetative person.

Soon, Guan Yanbin was controlled by the public security organs, resigned as chairman and general manager, and was then succeeded by him and his ex-wife's two daughters.

On January 31, 2019, Guan Yanbin was approved for arrest. On the same day, the eldest daughter Guan Yuxiu was elected by the board of directors as the chairman of Sunflower Pharmaceutical, and the second daughter Guan Yi became a member of the strategy committee of the board of directors and served as the convener of the strategy committee of the board of directors. In the end, Guan Yanbin committed intentional homicide and was sentenced to 11 years in prison. The second generation of succession is a foregone conclusion.

The founder is in prison, and although Sunflower Pharmaceutical urgently changes the coach, the shadow is still difficult to quickly eliminate. The market pessimism is strong, and the stock price of Sunflower Pharmaceutical continues to decline, at the lowest time it was only 12.02 yuan / share, down 48.5% from the peak of 23.34 yuan / share in 2018.

Sunflower Pharmaceutical's revenue declined for two consecutive years. In 2019 and 2020, the company's revenue was 4.371 billion yuan and 3.462 billion yuan, down 2.24% and 20.81% year-on-year, respectively.

The Kwan family has a firm grip on sunflower pharmaceuticals

The Kwan family still firmly controls sunflower pharmaceuticals. Guan Yanbin, who is in prison, is still the actual controller. Sunflower Pharmaceutical has 9 members on the board of directors, and Guan Yuxiu, Guan Yi and Guan Yanbin's brother Guan Yanling occupy three seats.

Sunflower Pharmaceutical Ginseng controls 24 enterprises, most of which are also legal representatives and executives by the Guan family. As a result, the Guan sisters have been succeeding for more than three years, and Sunflower Pharmaceutical's business initiatives and development strategies have maintained strong stability.

Sunflower Pharmaceutical is a brand pharmaceutical company based on proprietary Chinese medicines, of which children's medicine is the main track. A sentence "Little Sunflower Mother Class has started" makes the children's medicine brand "Little Sunflower" a household name.

Image source: Sunflower Pharmaceutical's official website

Sunflower Pharmaceutical has disclosed that Sunflower has focused on the children's drug market for 20 years, with annual retail sales of more than 10 billion yuan, sales of 300 million boxes, 69 children's special drug products on sale, accounting for nearly one-third of the market share of OTC pediatric drugs.

Whether in the era of Guan Yanbin or after the Guan sisters took the stage, Sunflower Pharmaceutical has adhered to the development strategy of small sunflower children's medicine as the main line. Less well known is that the strategy was forged by Sekiichi.

In 2002, at the age of 20, Guan Yi joined Sunflower Pharmaceutical. In the past 20 years, she has successively served as the deputy general manager of the advertising department, the general manager and general manager of the market management center of Sunflower Pharmaceutical, and is currently the director of Heilongjiang Jinkui Investment Co., Ltd., and the director and general manager of Sunflower Pharmaceutical.

In March 2020, Guan Yuxiu stressed that in the next 3 to 5 years, R&D, production and marketing resources will be further focused on the "children's medicine strategy", consolidate and expand the leading edge, and the two categories of "gynecology and the elderly" will be used as tactical supplementary growth and stable cultivation.

The Kwan sisters have also expanded their attention overseas, increasing the type of products through authorized introduction. According to the 2021 annual report, Sunflower Pharmaceutical acquired 6 children's drug varieties through the MAH model (Marketing Authorization Holder, drug marketing authorization), and at the same time obtained the domestic agency rights of two children's rare disease drugs hexenoic acid oral solution and trientine capsules of India Ruidi Pharmaceutical through the BD model (Business Development) and business development. On March 29, 2022, Sunflower Pharmaceutical signed a contract with the Danish company Mai Bo ApS to introduce three probiotic OTC drugs, one of which is atopic dermatitis in children.

For the commercialization of the above two children's rare disease drugs in China, the relevant person of the secretary of the board of directors of Sunflower Pharmaceutical explained that at present, the drug has not been marketed in China, "Due to the impact of the epidemic, the relevant procedures need to be gradually promoted." ”

For the future development plan of children's medicine, the person said that on the one hand, it is to expand the business horizontally, and on the other hand, to deepen the business vertically. "The company will expand the variety structure, dabble in more areas of drug use, and dig deep into the potential value of individual varieties in various ways." In addition to existing varieties, the company also has dormant varieties and varieties of external cooperation. ”

Under the helm of the Guan sisters, Sunflower Pharmaceutical continues the tradition of heavy marketing and light research and development. From 2019 to 2021, Sunflower Pharmaceutical's advertising and marketing expenses were 860 million yuan, 613 million yuan and 869 million yuan respectively, accounting for 19.67%, 17.77% and 19.71% of the company's revenue, respectively. The Times Weekly reporter noted that sunflower pharmaceutical research and development expenditure accounted for about 3% for three consecutive years, and the number of research and development personnel declined for three consecutive years, from 657 in 2018 to 535 today.

At the same time, the salary of the directors and supervisors of Sunflower Pharmaceutical has increased significantly. According to the financial report, in 2021, the company's directors and supervisors paid a total of 10.9642 million yuan, an increase of 72.82% over 6.3444 million yuan in 2020.

Among them, Guan Yuxiu, Guan Yi and Guan Yanling's pre-tax remuneration in 2021 was 1.1568 million yuan, 2.0226 million yuan and 797,300 yuan respectively. In 2020, their pre-tax compensation was $1.11 million, $930,000 and $558,200, respectively. Among them, Guanyi's salary increase was the highest, reaching 117.48%. "This is related to the performance of the executives themselves or other appraisals, which is a normal phenomenon." The relevant person of the board secretary office responded.

This article originated from the Time Weekly